InternationalUSRemember you can easily switch between MIP US and MIP International at any time

EPO revokes AstraZeneca’s pulmonary disease patent

Eklavya Gupte, London

One of AstraZeneca’s European patents covering Symbicort, a drug that treats pulmonary disease, has been revoked by the EPO following an appeal by generic manufacturers Norton Healthcare and Generics UK

The patent (EPB1014993) is one of two patents covering the Symbicort combination (formoterol and budesonide) used to treat chronic obstructive pulmonary disease.

The expiry date for the patent is 2018. The other patent covering the drug (EPB1210943) faces a separate...

Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

More from the Managing IP blog

null null null

null null null

November / December 2019

IP law: are the pressures taking their toll?

Following World Mental Health Day, Max Walters seeks the views of in-house professionals on whether they struggle with workplace pressures, and asks how to improve wellbeing

Most read articles